These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 9710113)

  • 21. Probability of pharmacodynamic target attainment with standard and prolonged-infusion antibiotic regimens for empiric therapy in adults with hospital-acquired pneumonia.
    Kim A; Kuti JL; Nicolau DP
    Clin Ther; 2009 Nov; 31(11):2765-78. PubMed ID: 20110018
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Febrile neutropenia: empiric antibiotic therapy from 1975 to 1997].
    Klastersky J
    Rev Med Brux; 1997 Oct; 18(5):323-7. PubMed ID: 9441328
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multicenter Evaluation of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Inhibitory Activity against Meropenem-Nonsusceptible Pseudomonas aeruginosa from Blood, Respiratory Tract, and Wounds.
    Grupper M; Sutherland C; Nicolau DP
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739780
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Monotherapy with meropenem in febrile granulocytopenic patients].
    Sanz MA; Jarque I; Larrea L
    Enferm Infecc Microbiol Clin; 1997 Sep; 15 Suppl 1():69-72. PubMed ID: 9410073
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The empirical antibiotic treatment of nosocomial spontaneous bacterial peritonitis: Results of a randomized, controlled clinical trial.
    Piano S; Fasolato S; Salinas F; Romano A; Tonon M; Morando F; Cavallin M; Gola E; Sticca A; Loregian A; Palù G; Zanus G; Senzolo M; Burra P; Cillo U; Angeli P
    Hepatology; 2016 Apr; 63(4):1299-309. PubMed ID: 26084406
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Left-sided endocarditis caused by Pseudomonas aeruginosa: successful treatment with meropenem and tobramycin.
    Gavin PJ; Suseno MT; Cook FV; Peterson LR; Thomson RB
    Diagn Microbiol Infect Dis; 2003 Oct; 47(2):427-30. PubMed ID: 14522517
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Piperacillin/tazobactam plus tobramycin versus ceftazidime plus tobramycin for the treatment of patients with nosocomial lower respiratory tract infection. Piperacillin/tazobactam Nosocomial Pneumonia Study Group.
    Joshi M; Bernstein J; Solomkin J; Wester BA; Kuye O
    J Antimicrob Chemother; 1999 Mar; 43(3):389-97. PubMed ID: 10223595
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Meropenem versus ceftazidime as empirical monotherapy in febrile neutropenia of paediatric patients with cancer.
    Fleischhack G; Hartmann C; Simon A; Wulff B; Havers W; Marklein G; Hasan C; Bode U
    J Antimicrob Chemother; 2001 Jun; 47(6):841-53. PubMed ID: 11389117
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of nosocomial pneumonia: an experience with meropenem.
    Santos SS; Machado FR; Kiffer CR; Barone AA
    Braz J Infect Dis; 2001 Jun; 5(3):124-9. PubMed ID: 11506775
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empirical therapy for neutropenic fever in children with malignancy.
    Hung KC; Chiu HH; Tseng YC; Wang JH; Lin HC; Tsai FJ; Peng CT
    J Microbiol Immunol Infect; 2003 Dec; 36(4):254-9. PubMed ID: 14723254
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prospective randomized comparison study of piperacillin/tazobactam and meropenem for healthcare-associated pneumonia in Japan.
    Yamamoto Y; Izumikawa K; Morinaga Y; Nakamura S; Kurihara S; Imamura Y; Miyazaki T; Tsukamoto M; Kakeya H; Yanagihara K; Yasuoka A; Kohno S
    J Infect Chemother; 2013 Apr; 19(2):291-8. PubMed ID: 23345050
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modelled target attainment after meropenem infusion in patients with severe nosocomial pneumonia: the PROMESSE study.
    Frippiat F; Musuamba FT; Seidel L; Albert A; Denooz R; Charlier C; Van Bambeke F; Wallemacq P; Descy J; Lambermont B; Layios N; Damas P; Moutschen M
    J Antimicrob Chemother; 2015 Jan; 70(1):207-16. PubMed ID: 25216821
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Equivalent efficacies of meropenem and ceftazidime as empirical monotherapy of febrile neutropenic patients. The Meropenem Study Group of Leuven, London and Nijmegen.
    J Antimicrob Chemother; 1995 Jul; 36(1):185-200. PubMed ID: 8537265
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: a report from the OPTAMA Program.
    Sun HK; Kuti JL; Nicolau DP
    Crit Care Med; 2005 Oct; 33(10):2222-7. PubMed ID: 16215374
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activity of cefepime and carbapenems in experimental pneumonia caused by porin-deficient Klebsiella pneumoniae producing FOX-5 beta-lactamase.
    Pichardo C; del Carmen Conejo M; Bernabéu-Wittel M; Pascual A; Jiménez-Mejías ME; de Cueto M; Pachón-Ibáñez ME; García I; Pachón J; Martínez-Martínez L
    Clin Microbiol Infect; 2005 Jan; 11(1):31-8. PubMed ID: 15649301
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Changing role of carbapenems in the treatment of lower respiratory tract infections.
    Lode H; Hamacher J; Eller J; Schaberg T
    Scand J Infect Dis Suppl; 1995; 96():17-23. PubMed ID: 7652498
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prospective evaluation of twice-daily cefotaxime in the treatment of hospitalized patients with severe infections.
    Keller C
    Diagn Microbiol Infect Dis; 1995; 22(1-2):159-61. PubMed ID: 7587032
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Meropenem monotherapy versus cefotaxime plus metronidazole combination treatment for serious intra-abdominal infections.
    Kempf P; Bauernfeind A; Müller A; Blum J
    Infection; 1996; 24(6):473-9. PubMed ID: 9007598
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patterns of antimicrobial therapy in severe nosocomial infections: empiric choices, proportion of appropriate therapy, and adaptation rates--a multicentre, observational survey in critically ill patients.
    Vogelaers D; De Bels D; Forêt F; Cran S; Gilbert E; Schoonheydt K; Blot S;
    Int J Antimicrob Agents; 2010 Apr; 35(4):375-81. PubMed ID: 20122817
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The role of carbapenems in the treatment of nosocomial infection].
    Martínez Lacasa J; Garau J
    Enferm Infecc Microbiol Clin; 1997 Sep; 15 Suppl 1():78-85. PubMed ID: 9410075
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.